Literature DB >> 11300867

Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.

T G Metzger1, M G Paterlini, D M Ferguson, P S Portoghese.   

Abstract

The delta-selective opioid antagonist naltrindole (NTI), as well as the kappa-selective opioid antagonists norbinaltorphimine (norBNI) and 5'-guanidinonaltrindole (GNTI), are derived from naltrexone, a universal opioid antagonist. Previous studies have indicated that extracellular loop III is the key region for discrimination by naltrexone-derived selective ligands between the delta, mu, and kappa opioid receptor types. It has been proposed that selective ligands could bind to all three receptor types if the appropriate portions of the extracellular loops were eliminated. To investigate this possibility, several single-point mutant opioid receptors have been generated with the aim of conferring enhanced affinity of selective ligands for their nonpreferred receptor types. Mutations were made in all three types of opioid receptors with the focus on two positions at the extracellular end of transmembrane regions (TM) VI and VII. It was found that the delta-selective NTI could bind both mu and kappa receptors with significantly enhanced affinity when an aromatic residue in TM VII was replaced with alanine (mu[W318A] and kappa[Y312A]). Similarly, kappa-selective antagonists, norBNI and GNTI, showed enhanced affinity for the mu[W318A] mutant and for both mu and delta receptors when a glutamate residue was incorporated into the extracellular end of TM VI (mu[K303E] and delta[W284E]). These results demonstrate that naltrexone-derived selective ligands achieve their selectivity via a combination of enhanced affinity of the address for a particular subsite along with loss of affinity due to steric interference at nonpreferred types. The results reveal key residues in the "address" recognition locus that contribute to the selectivity of opioid ligands and support the hypothesis that recognition of the naltrexone moiety is essentially the same for all three receptor types.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300867     DOI: 10.1021/jm000381r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.

Authors:  M Germana Paterlini
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

Review 2.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

Review 3.  Molecular recognition of opioid receptor ligands.

Authors:  Brian E Kane; Bengt Svensson; David M Ferguson
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

4.  Docking studies suggest ligand-specific delta-opioid receptor conformations.

Authors:  Vuk Micovic; Milovan D Ivanovic; Ljiljana Dosen-Micovic
Journal:  J Mol Model       Date:  2008-12-04       Impact factor: 1.810

Review 5.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

6.  Chemotype-selective modes of action of κ-opioid receptor agonists.

Authors:  Eyal Vardy; Philip D Mosier; Kevin J Frankowski; Huixian Wu; Vsevolod Katritch; Richard B Westkaemper; Jeffrey Aubé; Raymond C Stevens; Bryan L Roth
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

Review 7.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

8.  Computational insights into the subtype selectivity and "message-address-efficacy" mechanisms of opioid receptors through JDTic binding and unbinding.

Authors:  Jian-Xin Cheng; Tao Cheng; Wei-Hua Li; Gui-Xia Liu; Wei-Liang Zhu; Yun Tang
Journal:  Acta Pharmacol Sin       Date:  2017-10-19       Impact factor: 6.150

9.  Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity.

Authors:  Scott P Runyon; Lawrence E Brieaddy; S Wayne Mascarella; James B Thomas; Hernán A Navarro; James L Howard; Gerald T Pollard; F Ivy Carroll
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

10.  The effects of morphine, naloxone, and κ opioid manipulation on endocrine functioning and social behavior in monogamous titi monkeys (Callicebus cupreus).

Authors:  B J Ragen; N Maninger; S P Mendoza; K L Bales
Journal:  Neuroscience       Date:  2014-12-06       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.